Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-49. (Canceled)

50. (Currently Amended) A drug-oligomer conjugate having the formula:

$$D\text{-}H_p$$

wherein D is a therapeutic drug moiety selected from the group consisting of insulin, insulin lispro, and a functional equivalent of insulin;

H is a PEG polymer having from 1 to ~~10~~ 7 PEG units; and

p is a number from 1 to the maximum number of covalent bonding sites at which -H can form a bond with D.

51.-53. (Canceled)

54. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein the D-H bonds are non-hydrolyzable.

55. (Previously Presented) The drug-oligomer conjugate of claim 50, wherein the D-H bonds are selected from the group consisting of carbamate, amide and secondary amine.

56.-59. (Canceled)

60. (Currently Amended) The drug-oligomer conjugate of claim 5~~8~~0, wherein H is a PEG polymer having 2, 3, 4 or 5 PEG units.

61. (Currently Amended) The drug-oligomer conjugate of claim 5~~8~~0, wherein H is a PEG polymer having 3 PEG units.

62.-65. (Canceled)

66. (Previously Presented) A drug-PEG conjugate having the formula:

$$D\text{-}H_p$$

wherein D is selected from the group consisting of insulin, insulin lispro, and a functional equivalent of insulin;

H is a PEG polymer having from 1 to ~~10~~ 7 PEG units; and

p is a number from 1 to the maximum number of covalent bonding sites at which -H can form a bond with D,

wherein the drug-PEG conjugate has enhanced activity in comparison with a corresponding unconjugated insulin molecule, unconjugated insulin lispro molecule or unconjugated functional equivalent thereof.

67.-68. (Canceled)

69. (New) A method of treating an insulin deficiency comprising causing the drug-oligomer conjugate of claim 50 to circulate in the bloodstream of a subject.

70. (New) A method of treating an insulin deficiency comprising causing the drug-oligomer conjugate of claim 54 to circulate in the bloodstream of a subject.

71. (New) A method of treating an insulin deficiency comprising causing the drug-oligomer conjugate of claim 55 to circulate in the bloodstream of a subject.

72. (New) A method of treating an insulin deficiency comprising causing the drug-oligomer conjugate of claim 60 to circulate in the bloodstream of a subject.

73. (New) A method of treating an insulin deficiency comprising causing the drug-oligomer conjugate of claim 61 to circulate in the bloodstream of a subject.

74. (New) A method of treating an insulin deficiency comprising causing the drug-oligomer conjugate of claim 66 to circulate in the bloodstream of a subject.